Skip to main content
Premium Trial:

Request an Annual Quote

In Silico: Oct 1, 2002


www.GenomeWeb.COM Daily


Tool Talk


As big pharma’s product pipeline continues to wither, the role of genomics tools and data providers becomes increasingly uncertain. Will the pressure on pharma firms mean that genomic companies can expect an increase in new-technology orders? Or will pharma’s revenue woes mean increased spending becomes foolish?


Find “Genomic Tools Will Always Be a Must-Have for Big Pharma. Got 20 Years?” by searching: must-have


Not for Profit


Want to make money from open-source bioinformatics? As long as it’s not too much, you might have a chance. This was the verdict of a panel of academics and business executives who convened at Stanford University.


Find “How Good Is Greed for Open-Source Bioinformatics?” by searching: greed


Funding Famine?


Indian biotechnology companies, including those in the nation’s burgeoning bioinformatics sector, have enjoyed broad government support in recent years. Yet young biotechs in India are finding it exceedingly difficult to secure enough venture capital from risk-averse local investors, and tumbling stock markets in the US and Europe are hurting their chances of closing foreign private-equity deals.


Find “Facing Private-Equity Drought, Indian Biotech Hunkers Down” by searching: drought


www.BIOarraynews.COM WEEKLY


How to Beat the Big A?


In an effort to set themselves apart from Affymetrix, a number of companies poised to enter the gene expression chip market have promised to provide the “second generation” of microarrays. But what exactly does “second generation” mean? That depends largely on whom one asks. Pharmaceutical and biotechnology researchers have a range of expectations.


Find “Time for the Next Generation Arrays? Pharmas Lay Out Their Top Priorities “ by searching: priorities




Open-Source Snafu


“The regrettable aspect is that [the statement] really does confuse an issue that had been worked out for quite a few years, which is what open source is.”

— Lincoln Stein, Cold Spring Harbor Laboratory


Find “ISCB President Says Society Goofed in Bioinformatics Software Availability Statement” by searching: ISCB




Spec School


Beneath the wellspring of interest in proteomics, the question remains as to whether new entrants to the field really know what they’re doing. Scientists are searching for alternative means of acquiring skills in proteomics, and for the most part their options have been limited. But that may be changing thanks to training available through vendors, consultants, professional societies, and public-sector organizations.


Find “Providing Training in Protein MS Isn’t Easy, But Help May Be on the Way” by searching: training

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.